Plasma ACE and ACE2 Levels Are Altered in Patients with COVID-19
Viruses · 14.04.2026 · 18 (4) · 465
DOI: 10.3390/v18040465 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 14.04.2026. Verfasst von Murat Oz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, College of Pharmacy, Kuwait University, Safat 13110, Kuwait. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, COVID-19, Peptidyl-Dipeptidase A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was supported and funded by the Research Sector of the Kuwait University,, Research Sector of the Kuwait University.
Abstract (Originalsprache)
Objective: The COVID-19 pandemic has strained healthcare systems and has been associated with substantial morbidity and mortality. Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) enters host cells by binding to angiotensin-converting enzyme 2 (ACE2), implicating dysregulation of the renin–angiotensin system (RAS) in COVID-19 pathophysiology. Measurement of circulating RAS components, including ACE and ACE2, may therefore provide an insight into disease severity and underlying mechanisms. Subjects and Methods: In this retrospective cohort study, 224 adults with PCR-confirmed COVID-19 were stratified by World Health Organization disease-severity criteria into asymptomatic, mild, mild-pneumonia, severe, and critical groups. Plasma ACE and ACE2 concentrations were quantified by ELISA. Demographic, clinical, and laboratory data were extracted from electronic medical records. Results and Conclusions: Increasing disease severity was associated with higher mortality, elevated body mass index, and higher viral load estimates. Severe and critical illness was characterized by leukocytosis with neutrophilia, marked lymphopenia, anemia, elevated inflammatory and coagulation markers, renal dysfunction, and hypoalbuminemia. Plasma ACE2 levels declined progressively with increasing severity and were significantly lower in patients with mild-pneumonia, severe, or critical illness compared with asymptomatic or mild cases, showing a strong inverse correlation with severity. In contrast, plasma ACE levels increased significantly with disease severity. The resulting increase in the ACE/ACE2 ratio indicates a progressive shift toward the pro-inflammatory arm of the RAS, providing mechanistic insight into the COVID-19 pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutics, College of Pharmacy, Kuwait University, Safat 13110, Kuwait.
- Department of Microbiology, Faculty of Medicine, Kuwait University, Safat 13110, Kuwait.
- College of Medicine, QU Health, Qatar University, Doha 2713, Qatar.
ORCID-Profile: Murat Oz, Wassim Chehadeh
Förderung
- This work was supported and funded by the Research Sector of the Kuwait University,
- Research Sector of the Kuwait University
Zitieren
APA
Oz, M., Chehadeh, W., Alfarisi, O., & Cyprian, F. S. (2026). Plasma ACE and ACE2 Levels Are Altered in Patients with COVID-19. Viruses, 18(4), 465. https://doi.org/10.3390/v18040465
Vancouver
Oz M, Chehadeh W, Alfarisi O, Cyprian FS. Plasma ACE and ACE2 Levels Are Altered in Patients with COVID-19. Viruses. 2026;18(4):465. doi:10.3390/v18040465
BibTeX
@article{Oz2026,
author = {Oz, Murat and Chehadeh, Wassim and Alfarisi, Omamah and Cyprian, Farhan S},
title = {Plasma ACE and ACE2 Levels Are Altered in Patients with COVID-19},
journal = {Viruses},
year = {2026},
volume = {18},
number = {4},
pages = {465},
doi = {10.3390/v18040465}
}
EUVIMED